Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus.

Doreau, Agnès; Belot, Alexandre; Bastid, Jérémy; Riche, Benjamin; Trescol-Biemont, Marie-Claude; Ranchin, Bruno; Fabien, Nicole; Cochat, Pierre; Pouteil-Noble, Claire; Trolliet, Pierre; Durieu, Isabelle; Tebib, Jacques; Kassai, Berhouz; Ansieau, Stéphane; Puisieux, Alain; Eliaou, Jean-François; Bonnefoy-Bérard, Nathalie.
Nat Immunol; 10(7): 778-85, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19483719
Studies have suggested involvement of interleukin 17 (IL-17) in autoimmune diseases, although its effect on B cell biology has not been clearly established. Here we demonstrate that IL-17 alone or in combination with B cell-activating factor controlled the survival and proliferation of human B cells and their differentiation into immunoglobulin-secreting cells. This effect was mediated mainly through the nuclear factor-kappaB-regulated transcription factor Twist-1. In support of the relevance of our observations and the potential involvement of IL-17 in B cell biology, we found that the serum of patients with systemic lupus erythematosus had higher concentrations of IL-17 than did the serum of healthy people and that IL-17 abundance correlated with the disease severity of systemic lupus erythematosus.
Selo DaSilva